Journal
CLINICAL INFECTIOUS DISEASES
Volume 52, Issue -, Pages S326-S330Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/cir047
Keywords
-
Categories
Funding
- Food and Drug Administration
- Infectious Diseases Society of America
- AstraZeneca Pharmaceuticals
- Bio Merieux, Inc.
- Cepheid
- Gilead Sciences
- Intelligent MDX, Inc.
- Inverness Medical Innovations
- Roche Molecular Systems
- Qiagen
- Roche Molecular
Ask authors/readers for more resources
Molecular methods are becoming more widely used for the detection of respiratory pathogens, in part because of their superior sensitivity, relatively rapid turnaround time, and ability to identify pathogens that are slow growing or difficult to culture. The recent novel H1N1 influenza A pandemic served to underscore how quickly new molecular tests can become available for clinical use. Over the years PCR has been the dominant amplification method. Recently, modifications of this technology have emerged, some of which allow for the rapid detection of multiple pathogens in a single test. This review will focus on emerging multiplex molecular technologies and their clinical utility for the detection of respiratory pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available